Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology
Disease Category: Non-Hodgkin's Lymphoma

Trial Information

A Phase I Open Label Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

You have been asked to participate in this research study because you have Cutaneous T-cell Lymphoma (CTCL) that has either relapsed (returned after initially responding to previous treatment) or is refractory (has not responded to previous treatment). The purpose of this study is to evaluate the safety and effectiveness of different doses of the investigational drug pralatrexate given with vitamin B12 and folic acid supplementation. Every subject enrolled will receive pralatrexate, vitamin B12 and folic acid. Treatment is expected to last up to 12 months, however, if your doctor feels that there is clinical or radiological evidence of benefit, you may receive additional treatment cycles. After your treatment on this study is over, your medical condition will continue to be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.